Pain and Placebo
Sandeep Kapur1, Rosy Dunham* and Shyam Balasubramanian2

1Consultant in Pain Medicine & Anaesthesia, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
2Department of Anaesthetic, West Midlands Central Deanery, Birmingham, UK
3Consultant in Pain Medicine & Anaesthesia, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK

Abstract
Expectation of pain relief can reduce pain and prior positive experiences increase the analgesic responses to subsequent placebo. Placebo effect is the positive beneficial response after receiving a placebo. Nocebo effects are the negative responses after receiving a placebo which are usually minor, but can be life threatening. Endogenous neuropeptides such as opioids, dopamine, serotonin and cannabinoids are released in placebo analgesia. Part of the placebo response is mediated by intrinsic cognitive factors, alone or in combination with extrinsic environmental factors.

Keywords: Pain; Placebo; Nocebo

Introduction
Medical literature has been describing placebos and their effects for more than two hundred years, and the quest to understand the mechanisms and explore the applications is still expanding. Placebo for pain relief is perhaps the most well understood model with clearly defined neurobiological mechanisms [1].

The placebo effect describes ‘the positive response some patients / participants experience after receiving a placebo’. Placebo is in turn defined as ‘any therapy or component of therapy used for its nonspecific, psychological, or psychophysiological effect, or that is used for its presumed specific effect, but is without specific activity for the condition being treated’ [2]. This response has a beneficial effect, measurable either subjectively or objectively. These effects are related to intrinsic factors (e.g., personal expectations) either alone or in combination with extrinsic factors (e.g., environment, relationship with healthcare provider) [3].

Conversely, the Nocebo effect is ‘the negative response some patients / participants experience after receiving a placebo’. These effects are usually minor (e.g., headache, nausea) but can extend to life threatening (e.g., cardiac arrest) [3].

History
In medieval times, mourners were hired to attend funerals, but because their emotions were considered insincere, they were called ‘Placebos’, from the Latin for ‘I will please’ [4]. Nocebo derives from the word nocere, meaning ‘I shall harm’. For centuries placebos were perceived as morally useful and therapeutically precious, though they continued to evoke mixed feelings among clinicians. Indeed in 1803, Thomas Jefferson famously condemned the cynical use of placebo as a ‘pious fraud’ [4].

Despite the scepticism of Jefferson and others, the use of placebo was widespread in medicine until the first half of the twentieth century. After World War two, the respect for patient autonomy encouraged a debate over the ethical use of placebos in clinical practice. Moreover, an emphasis on transparency and candour in clinical practice meant that the traditional application of placebo was increasingly challenged [5].

In 1955, Henry Beecher, an eminent anaesthetist and medical ethicist, published a paper titled ‘The powerful placebo’, in which he stated, ‘Placebos have a high degree of therapeutic effectiveness in treating subjective responses’ [6]. This paper, in which he noted that placebos are effective 30% of the time, has been cited over a thousand times. Although in retrospect Beecher’s paper has been criticised for methodological flaws, at that time it had a profound effect on clinical research by advocating the use of placebo in the control group of randomised trials [4].

Two decades after Beecher, in a seminal paper, Levine and colleagues investigated the role of endorphins within the placebo effect. Following a dental procedure, patients were randomised to receive either morphine (treatment) or saline (placebo) injection. Patients from the placebo arm of the study were then separated into placebo-responders and non-responders. Both groups were then administered intravenous naloxone. The placebo responders reported increased pain following the naloxone injection, whereas the placebo non-responders showed no change in their pain scores, hence proving that endogenous endorphin production was the likely cause for the positive placebo effect in the group that initially responded to the saline injection [7]. Currently, many theories are postulated as possible explanations for the placebo effect.

Mechanisms of Placebo Analgesia
Pain relief by placebo is explained by psychological mechanisms (e.g., expectation, conditioning) and neurobiological mechanisms (e.g., endorphins, dopamine, serotonin, cannabinoids). The nocebo hyperalgesic response may be due to activation of the cholecystokininergic systems and is predisposed by psychological mechanisms such as anxiety and expectation of pain [8]. (Figure-1). When compared to the placebo effect, studies investigating the nocebo effect are relatively few due to the ethical difficulties involved, since nocebos trigger negative outcomes.

Psychological Mechanisms
Expectation of pain relief can induce placebo analgesia. Positive previous experiences can accentuate the placebo induced analgesic responses. Similarly, negative previous experiences attenuate the response to a subsequent placebo [9]. When these conditioning
techniques are repeatedly combined with analgesic treatments, they can evoke a clinical effect similar to the response produced by the analgesic medications. For example, a placebo given after a repetitive administration of opioids produces opioid-like effects such as reducing the intensity of pain, and also opioid-induced adverse events, such as nausea [10]. Traits such as empathy, optimism, and altruism demonstrated by the clinician have been linked to reinforcing the effectiveness of placebo analgesia [10].

**Neurobiological Mechanisms**

Placebo analgesic effects have been demonstrated to activate different brain areas including the Dorsolateral Prefrontal Cortex, the rostral Anterior Cingulate Cortex and subcortical regions including the Hypothalamus, Amygdala and the Periaqueductal Gray. The Dorsolateral Prefrontal Cortex initiates the placebo analgesic response. The rostral Anterior Cingulate Cortex is connected to the Periaqueductal Gray and correlates with the modulation of placebo analgesia. These then connect to the descending pain inhibitory system involved in pain modulation [10]. It has been demonstrated that placebo analgesia is mediated by the release of endogenous neuropeptides such as opioids, dopamine, serotonin and cannabinoids [11].

**Placebo and Brain Imaging**

Although supraspinal cognitive and affective structures are thought to be involved in processing pain signals, the biological mechanisms are yet to be adequately elucidated. Brain imaging techniques such as functional magnetic resonance imaging (fMRI) and positron emission topography (PET) are beginning to provide an understanding of the central opioidergic system, and the changes produced by placebo effect on the central processing of pain [12]. Brain imaging studies suggest that placebo activates the same opioid receptor system to which remifentanil, a specific mu receptor agonist, binds [13]. Other fMRI studies identified that placebo analgesia is associated with reduced brain activity in pain sensitive brain areas like thalamus, thereby providing evidence that placebo alters the experience of pain [14]. FMRI studies have also shown that placebo analgesia reduces nociceptive processing in the spinal cord, suggesting that top-down mechanisms suppress pain processing in the central nervous system at the earliest stages.

**Genetics and the Placebo Response**

The study of the genomic effects on placebo response is termed the ‘placebome’. Several recent studies have explored the possibility that placebo responders share specific genetic and personality traits [15]. The analgesic effects of placebo have been shown to be mediated through activation of endogenous opioid as well dopaminergic and serotonergic mechanisms. However, genetic polymorphism in the expressing of these mechanisms may mean that placebo responses vary by genotype. Hall and others have identified 28 genes that are associated with 54 proteins, which can result in meaningful variation in the outcomes of the placebo arms of clinical trials. This genetic variation particularly relates to analgesics and antidepressants [16].

In randomised controlled trials, the placebo arm is commonly considered to be an adequate control for outcomes in the active treatment arm. But, if the placebo response varies by genotype, the potential ‘gene-drug-placebo effect’ modification can make it challenging to interpret the results. Therefore, in order to improve the reliability and reproducibility of placebo controlled trials, a greater understanding of the role of the genetic influences in predicting placebo effect is essential.

**Ethical Considerations**

The current ethical debate over the clinical use of placebos hinges on whether it is permissible for clinicians to deceive patients in order to benefit them. While some authorities categorically reject the use of deceptive placebos, others argue that their therapeutic value justifies their use in certain circumstances. The American Medical Association’s position on placebo is that ‘physicians may use placebos for diagnosis or treatment only if the patient is informed of and agrees its use’ [17]. Guidelines have been developed for ethical use of placebo in the clinical and research environment [18, 19]. (Table 1)

While these guidelines may appear to be rigid and discourage the use of placebo in clinical and research arenas, in practice they offer a framework upon which ethical placebo use can be based.
the placebo effect has been an ongoing topic of discussion. Placebo trials for new analgesic medications. In the last decade, more than 90% of companies are finding it harder to conduct placebo controlled clinical trials, largely due to an increase in the placebo effect. No significant change in placebo responses was observed in similar trials in Europe, Asia and Australia. The Hawthorne (or Observer) effect may also be contributory: a placebo may indirectly augment patients' expectations, leading to an increase in the placebo response. As randomized controlled trials do. The authors postulate "engendering hope when participants feel hopeless about their condition can be therapeutic" [21]. The Hawthorne (or Observer) effect may also be contributory: a person who is aware of being studied /observed may feel better, even if nothing has actually changed [4].

An intriguing phenomenon recently identified is that placebo responses are raising only in the United States. In 1996, patients in clinical trials described that drugs relieved their pain by 27% more than a placebo. By 2013, that gap had reduced to just 9% in United States clinical trials, largely due to an increase in the placebo effect. No significant change in placebo responses was observed in similar trials in Europe, Asia and elsewhere. One possible explanation is that direct-to-consumer drug advertising is allowed in the United States and this has increased people's expectations of the benefits of drugs, creating stronger placebo effects. Moreover, big, well-funded United State trials, and the glamour and gloss of their presentation might indirectly augment patients' expectations, leading to an increase in the placebo response. As a consequence, pharmaceutical companies are finding it harder to conduct placebo controlled clinical trials for new analgesic medications. In the last decade, more than 90% of potential drugs for treatment of cancer and neuropathic pain have failed at advanced phases of clinical trials [22].

**Applications of Placebo**

Translating placebo research into better patient care by harnessing the placebo effect has been an ongoing topic of discussion. Placebo effects have an important role in at least three areas [23]. As controls in experimental studies to determine specific effects and to enable blinding, in placebo research to study placebo effects, As a tool in clinical practice.

Whereas the role of placebo in research is well established, the use of therapeutic placebo in clinical practice remains controversial. The Institute of Medicine (USA) opines that 'Placebo can conceivably be a form of treatment of pain, especially in light of the shortcomings of other modalities or benefits they bring in their (own) right' [20]. Historically, research on the factors that increase placebo response has focused on attributes of the treatment, showing that more invasive treatment modalities or specific pill colours are associated with higher placebo response rate, supporting the view that structured manipulation of physicians' verbal and non-verbal performance may have a significant beneficial effect on the size of response to placebo analgesia [24]. Physicians can produce a placebo-like effect through the skillful use of reassurance, encouragement and mutual respect, thereby improving health outcomes [17]. Studies have also demonstrated that patient education enhances perceptions of placebo knowledge, effectiveness and acceptability, even in deceptive treatment contexts [1]. It is possible that if physicians understood the mechanisms underlying placebo treatments, they may be more open with their patients when using this modality, particularly when used in conjunction with existing pain interventions to improve overall treatment effectiveness.

Barrett and others have proposed certain practical principles that clinicians can use to elicit placebo effects in order to enhance the feeling of being cared for, reduce anxiety, and reinforce positive expectations. These principles include: speaking about treatments in a positive light, fostering trust, providing reassurance and encouragement, building relationships, treating each patient as unique, exploring their values, and "creating ceremony" [25].

**Conclusion**

Over the last three decades, understanding of the complex mechanisms behind the placebo effect has improved considerably, with a clearer understanding of the alterations in central pain processing caused by placebo. Ethical concerns continue to persist, however; placebo is therefore less likely to be promoted as a stand-alone intervention if there is an evidence-based alternative. Scientific advances elucidating placebo's psychological and neurobiological mechanisms have reinforced continued exploration of ethically acceptable placebo applications to facilitate better health outcomes. A better understanding of nocebo may also help in developing preventive measures by identifying factors that lead to maladaptive responses. Structured training in enhancing patient-doctor interactions is also likely to have a beneficial effect by potentiating the placebo response. r prevention of disease progression in osteoarthritis knee patients.
References


19. Journal of Medical Ethics; 30: 551-554


